AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
Key facts
- Who runs it
- University of Manitoba
- Where
- Camden, Chicago, Dearborn, Jefferson, Milwaukee, and Portland, United StatesSee the 6 sitesAlso in 3 other countries, 62 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 4,000 people, planned
- Started
- 10 Oct 2023
- Expected to end
- 31 Mar 2029
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Heparin
- Record updated
- 30 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Patients ≥18 years of age
- Admitted to hospital for a suspected or confirmed diagnosis of CAP defined by:; Radiographic evidence of new or worsening infiltrate; One or more of the following signs and/or symptoms of lower respiratory tract infection; New or increased cough or sputum production ii. Fever of > 37.8C or temperature < 36C iii. WBC > 11 x 109/L or < 4 x 109/L c. The primary diagnosis is believed to be CAP as per the attending physician
- Requires supplemental oxygen to treat hypoxemia (or requires an increased level of supplemental oxygen if on chronic oxygen therapy)
- Hospital admission anticipated to last ≥72 hours from randomization
Who cannot take part
- Hospital admission for >72 hours prior to randomization
- Patients receiving non-invasive or invasive ventilation, vasopressors, or extracorporeal life support (ECLS) within an ICU at the time of enrollment
- Requirement for chronic mechanical ventilation via tracheostomy prior to hospitalization
- Enrollment in other interventional trials related to anticoagulation or antiplatelet therapy during current hospitalization
- Suspected or confirmed active COVID-19 infection
- History of heparin induced thrombocytopenia (HIT) or other heparin allergy
- Patients with a contraindication to therapeutic-dose anticoagulation, including:; Non-traumatic bleeding that requires medical evaluation or hospitalization within 30 days prior to CAP hospital admission; History of an inherited or acquired bleeding disorder; Cerebral aneurysm or mass lesions of the central nervous system; Ischemic stroke within 3 months of hospital admission; Gastrointestinal bleeding within 3 months of hospital admission; Platelet count <50 x109/L OR INR >2.0 OR hemoglobin <80 g/L at the time of screening; Other physician-perceived contraindications to therapeutic anticoagulation
- Current or recent (within 7 days of screening) use of dual anti-platelet inhibitors (For example; Aspirin + one of the following; clopidogrel, ticagrelor, prasugrel)
- Patients for whom the intent is to not use pharmacologic thromboprophylaxis
- Patients with an independent indication for therapeutic-dose anticoagulation
- Patients in whom imminent death is anticipated
- Anticipated transfer to another hospital that is not a study site within 72 hours of randomization
Where in United States
Also in 3 other countries, 62 sites
- Cooper University Health CareCamden, United StatesContact: Adam Green, MDTaking people
- University of ChicagoChicago, United StatesContact: Jonathan Paul, MDTaking people
- Henry Ford Health SystemDearborn, United StatesContact: Chantale PineauNo longer taking part
- Ochsner ClinicJefferson, United StatesContact: Derek Vondehaar, MDTaking people
- Medical College of WisconsinMilwaukee, United StatesContact: Alisha Sharma, MDTaking people
- Maine Medical CentrePortland, United StatesContact: Daniel Meyer, MDTaking people
About the trial
What the trial wants to find out
This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).
The 2 groups in the trial
- Therapeutic-Dose HeparinTreatment being tested
Participants randomized to the investigational arm will receive a pragmatic strategy of therapeutic-dose low molecular-weight heparin (LMWH) or unfractionated heparin (UFH) administered daily for up to 14 days or until hospital discharge, whichever occurs first. Participants should start receiving study drug as soon as possible following randomization.
Treatment: Heparin
- Usual CareNo study treatment, for comparison
Participants randomized to the control arm will receive usual care thromboprophylactic dose anticoagulation according to local practice. To ensure adequate separation between the study groups, the dose of heparin/LMWH used in the usual care arm should not equal more than half of the approved therapeutic dose for that agent according to local VTE treatment protocols.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 30 September 2026